Press Release

Wednesday, 27 April 2022

European Journal for Cardiothoracic Surgery publishes ESPOIR 5-year data

A 5-year analysis of ESPOIR Trial patients was performed to provide an insight into the midterm performance of decellularized pulmonary homografts (DPH). ESPOIR Trial and Registry patients were matched with cryopreserved homografts (CH) patients considering patient age, type of heart defect and previous procedures to present the overall experience with DPH. The 5-year data of the prospective ESPOIR Trial showed excellent performance for DPH and low rates of adverse events. ESPOIR Registry data up to 15 years, including a matched comparison with CH, demonstrated statistically significant better freedom from explantation.   The Open Access full article is available here (paste into your browser):